FDA.reportPublic FDA data

15 ML natalizumab 20 MG/ML Injection

RxCUI
477484
RxNorm name
15 ML natalizumab 20 MG/ML Injection
Display name
15 ML natalizumab 20 MG/ML Injection
Full name
15 ML natalizumab 20 MG/ML Injection
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:20

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125104Tysabrinatalizumab351(a)Rx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
c5fdde91-1989-4dd2-9129-4f3323ea2962natalizumab 300 MG in 15 ML Injection [PSN] · 15 ML natalizumab 20 MG/ML Injection [SCD] · natalizumab 300 MG per 15 ML Injection [SY]347These highlights do not include all the information needed to use TYSABRI safely and effectively. See full prescribing information for TYSABRI. TYSABRI (natalizumab) injection, for intravenous use Initial U.S. Approval: 200420250321